NCT05978713View on ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) in Healthy Lactating Females

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

March 12, 2024

Study Completion Date

March 12, 2024

Conditions
Healthy
Interventions
DRUG

Tirzepatide

Administered SC

Trial Locations (1)

89113-2228

Las Vegas Clinical Research Unit - PPD, Las Vegas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05978713 - A Study of Tirzepatide (LY3298176) in Healthy Lactating Females | Biotech Hunter | Biotech Hunter